曲妥珠单抗耐药机制及HER2阳性乳腺癌耐药后的治疗策略

doi:10.11904/j.issn.1002-3070.2022.05.010

摘要/Abstract

摘要： 曲妥珠单抗治疗人表皮生长因子受体2(Human epidermal growth factor receptor 2,HER2)阳性乳腺癌的效果确切,但高耐药率限制了其临床应用。本文对HER2阳性乳腺癌曲妥珠单抗耐药机制进行回顾与总结,并分析耐药后HER2阳性乳腺癌的治疗策略,以期为进一步的研究及临床治疗方案制定提供参考。

关键词: 曲妥珠单抗耐药, HER2阳性乳腺癌, 机制, 治疗

Abstract: Trastuzumab is effective in the treatment of human epidermal growth factor receptor 2(HER2)positive breast cancer,but the high drug resistance rate limits its clinical application.This article reviews and summarizes the mechanism of trastuzumab resistance in HER2-positive breast cancer,and analyzes the treatment strategies for HER2-positive breast cancer after drug resistance,in order to provide reference for further research and clinical treatment plan formulation.

Key words: Trastuzumab resistance, HER2-positive breast cancer, Mechanisms, Treatment

中图分类号:

R737.1

王星涵, 吕雅蕾. 曲妥珠单抗耐药机制及HER2阳性乳腺癌耐药后的治疗策略[J]. 实用肿瘤学杂志, 2022, 36(5): 445-451.

WANG Xinghan, LV Yalei. Mechanisms of trastuzumab resistance and post-resistance treatment strategies in HER2-positive breast cancer[J]. Journal of Practical Oncology, 2022, 36(5): 445-451.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.05.010

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I5/445

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Wang RX,Chen S,Jin X,et al.Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer:loss of HER2 amplification and its impact on response and prognosis[J].Breast Cancer Res Treat,2017,161(2):259-267.
3 Swain SM,Baselga J,Kim SB,et al.Pertuzumab,trastuzumab,and docetaxel in HER2-positive metastatic breast cancer[J].N Engl J Med,2015,372(8):724-734.
4 Sonnenblick A,Bailey A,Uziely B,et al.Autoimmunity and benefit from trastuzumab treatment in breast cancer:results from the HERA trial[J].Anticancer Res,2019,39(2):797-802.
5 Marty M,Cognettlf,Maraninchi D,et al.Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:the M77001 study group[J].J Clin Oncol,2005,23(19):4265-4274.
6 Singer CF,Köstler WJ,Hudelist G.Predicting the efficacy of trastuzumab-based therapy in breast cancer:current standards and future strategies[J].Biochim Biophys Acta,2008,1786(2):105-113.
7 Venkatesan P.Trastuzumab emtansine for HER2-positive breast cancer[J].Lancet Oncol,2016,17(12):528.
8 Koygun GK,Kars MD,Emsen A,et al.Response to trastuzumab and investigation of expression profiles of matrix metalloproteinase-related proteins in primary breast cancer stem cells[J].Clin Exp Med,2021,21(4):447-456.
9 Zong Y,Pegram M.Research advances and new challenges in overcoming triple-negative breast cancer[J].Cancer Drug Resist,2021,4(3):517.
10 Adamczyk A,Kruczak A,Harazin-Lechowska A,et al.Relationship between HER2 gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment[J].Onco Targets Ther,2018,11:4525-4535.
11 Wu Z,Xu S,Zhou L,et al.Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting[J].Onco Targets Ther,2018,11:801-808.
12 Cordo Russo RI,Beguelin W,Flaqué D,et al.Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance[J].Oncogene,2015,34(26):3413-3428.
13 Saranya C,Jeff S,Heshan L,et al.High p95HER2/HER2 ratio associated with poor outcome in trastuzumab-treated HER2 -positive metastatic breast cancer NCCTG N0337 and NCCTG 98-32-52(Alliance)[J].Clin Cancer Res,2018,24(13):3053-3058.
14 Murad R,Avanes A,Ma X,et al.Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+ breast cancer cells[J].Gene,2021,799(5):145808.
15 Wimana Z,Gebhart G,Guiot T,et al.N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging[J].Oncotarget,2017,8(34):56185-56198.
16 Keegan NM,Furney SJ,Walshe JM,et al.Phase Ib Trial of copanlisib,a phosphoinositide-3 kinase(PI3K)inhibitor,with trastuzumab in advanced pre-treated HER2-positive breast cancer“PantHER”[J].Cancers,2021,13(6):1225.
17 Areti S,Martha Z,Galatea K,et al.A comprehensive molecular analysis of in vivo isolated EpCAM-positive circulating tumor cells in breast cancer[J].Clin Chim,2021,67(10):1395-1405.
18 Yokoyama D,Hisamori S,Deguchi Y,et al.PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma[J].Sci Rep,2021,11(1):9013.
19 O'Brien NA,McDonald K,Tong L,et al.Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT[J].Clin Cancer Res,2014,20(13):3507-3520.
20 Sun Y,Li C,Pang S,et al.Kinase–substrate edge biomarkers provide a more accurate prognostic prediction in ER-negative breast cancer[J].Genomics Proteomics Bioinformatics,2021,18(5):525-538.
21 Daverey A,Drain AP,Kidambi S.Physical intimacy of breast cancer cells with mesenchymal stem cells elicits trastuzumab resistance through Src activation[J].Sci Rep,2015,5(1):13744.
22 孔鸿儒,戴胜杰,陈豪,等.α-龙葵碱通过WNT信号通路抑制曲古抑菌素A-耐药人胰腺癌细胞的上皮-间质转化进程[J].肝胆胰外科杂志,2020,32(2):89-96.
23 师锐赞,何倚帆,牛亚楠,等.上皮黏附分子通过诱导EMT促乳腺癌转移和耐药[J].中国药理学通报,2021,37(7):934-939.
24 Shu X,Hildebrandt MA,Gu J,et al.MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity[J].Brit J Cancer,2017,116(1):77-84.
25 Sajadimajd S,Yazdanparast R,Akram S.Involvement of numb-mediated HIF-1 inhibition in anti-proliferative effect of PNA-antimiR-182 in trastuzumab-sensitive and -resistant SKBR3 cells[J].Tumour Biol,2016,37(4):5413- 5426.
26 Eto K,Iwatsuki M,Watanabe M,et al.The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab[J].Ann Surg Oncol,2014,21(1):343-350.
27 Tehrani SS,Zaboli E,Sadeghi F,et al.MicroRNA-26a-5p as a potential predictive factor for determining the effectiveness of trastuzumab therapy in HER2 positive breast cancer patients[J].Bio Medicine,2021,11(2):30-39.
28 Han M,Qian X,Cao H,et al.LncRNA ZNF649-AS1 induces trastuzumab resistance by promoting ATG5 expression and autophagy[J].Mol Ther,2020,28(11):2488-2502.
29 Tan AR,Im SA,Mattar A,et al.Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer(FeDeriCa):a randomised,open-label,multicentre,non-inferiority,phase 3 study[J].Lancet Oncol,2021,22(1):85-97.
30 Díaz-Acedo R,Artacho-Criado S,Galván-Banqueri M,et al.Real world study of pertuzumab-trastuzumab chemotherapy versus trastuzumab-chemotherapy in neoadjuvant treatment of breast cancer[J].Farm Hosp,2020,44(3):96-99.
31 Verma S,Miles D,Gianni L,et al.Trastuzumab emtansine for HER2-positive advanced breast cancer[J].New Eng J Med,2012,367(19):1783-1791.
32 Welslau M,Diéras V,Sohn JH,et al.Patient-reported outcomes from EMILIA,a randomized phase 3 study of trastuzumab emtansine(T-DM1)versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer[J].Cancer,2014,120(5):642-651.
33 Krop IE,Kim SB,Gonzlez-Martín A,et al.Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer(TH3RESA):a randomised,open-label,phase 3 trial[J].Lancet Oncol,2014,15(7):689-699.
34 刘婷,陈蕾,于力.曲妥珠单抗共轭复合物对HER2阳性乳腺癌疗效及用药安全性的Meta分析[J].中华肿瘤防治杂志,2021,28(17):1345-1354.
35 Modi S,Saura C,Yamashita T,et al.Trastuzumab deruxtecan in previously treated HER2-positive breast cancer[J].N Engl J Med,2020,382(7):610-621.
36 Cortés J,Kim SB,Chung WP,et al.LBA1 trastuzumab deruxtecan(T-DXd)vs trastuzumab emtansine(T-DM1)in patients(pts)with HER2+ metastatic breast cancer(mBC):results of the randomized phase III DESTINY-Breast03 study[J].Ann Oncol,2021,32:1287-1288.
37 Zhang J,Ji D,Shen W,et al.Abstract PD8-04:Safety and anti-tumor activity of ARX788 in HER2-positive metastatic breast cancer patients whose disease is resistant/refractory to HER2 targeted agents(trastuzumab,ADCs,TKIs,and bispecific antibodies):ACE-Breast-01 trial results[J].Cancer Res,2022,82(4 Suppl):PD8-04.
38 Wang J,Liu Y,Zhang Q,et al.RC48-ADC,a HER2-targeting antibody-drug conjugate,in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer:a pooled analysis of two studies[J].J Clin Oncol,2021,39(15 Suppl):1022.
39 Xu B,Wang J,Zhang Q,et al.An open-label,multicenter,phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer[J].J Clin Oncol,2018,36(15):1028.
40 Xu B,Wang J,Fang J,et al.Abstract PD4-06:early clinical development of RC48-ADC in patients with HER2 positive metastatic breast cancer[J].Cancer Res,2020,80(4):10-14.
41 Gong J,Shen L,Wang W,et al.Safety,pharmacokinetics and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer[J].J Clin Oncol,2018,36(15):16059.
42 Rugo HS,Pegram MD,Gradishar WJ,et al.SOPHIA:a phase 3,randomized study of margetuximab(M)plus chemotherapy(CTX)vs trastuzumab(T)plus CTX in the treatment of patients with HER2+ metastatic breast cancer(MBC)[J].J Clin Oncol,2016,34(15):630.
43 Manich CS,O'Shaughnessy J,Aftimos PG,et al.LBA15 primary outcome of the phase III SYD985.002/TULIP trial comparing vic trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer[J].Ann Oncol,2021,32:1288.
44 Hu X,Zhang J,Liu R,et al.Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors[J].J Clin Oncol,2021,39(15):1024.
45 黄文发,严颖,张如艳,等.曲妥珠单抗和拉帕替尼在辅助曲妥珠单抗治疗后一线复发的HER2阳性晚期乳腺癌治疗中疗效的比较[J].肿瘤,2020,40(9):641-649.
46 Nishimura R,Toh U,Tanaka M,et al.Role of HER2-related biomarkers(HER2,p95HER2,HER3,PTEN,and PIK3CA)in the efficacy of lapatinib plus capecitabine in HER2-positive advanced breast cancer refractory to trastuzumab[J].Oncology,2017,93(1):51-61.
47 Chan A,Moy B,Mansi J,et al.Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial[J].Clin Breast Cancer,2020,21(1):80-91.
48 Blackwell KL,Zaman K,Tkaczuk KHR,et al.Neratinib in combination with trastuzumab for the treatment of patients with advanced HER2-positive breast cancer:a phase I/II study[J].Nat Rev Cancer,2019,19(2):97-104.
49 Freedman RA,Gelman RS,Wefel JS,et al.Translational breast cancer research consortium(TBCRC)022:a phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases[J].J Clin Oncol,2016,34(9):945-952.
50 André F,O'Regan R,Ozguroglu M,et al.Everolimus for women with trastuzumab-resistant,HER2-positive,advanced breast cancer(BOLERO-3):a randomised,double-blind,placebo- controlled phase 3 trial[J].Lancet Oncol,2014,15(6):580-591.
51 Keck S,Glencer AC,Rugo HS.Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer[J].Future Oncol,2012,8(11):1383-1396.
52 Vernieri C,Corti F,Nichetti F,et al.Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer:targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications[J].Breast Cancer Res,2020,22(1):1-13.
53 Mezynski MJ,Farrelly AM,Cremona M,et al.Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer[J].J Transl Med,2021,19(1):184.
54 Wisinski KB,Tevaarwerk AJ,Burkard ME,et al.Phase I study of an AKT inhibitor(MK-2206)combined with lapatinib in adult solid tumors followed by dose expansion in advanced HER2+ breast cancer[J].Clin Cancer Res,2016,22(11):2659-2667.

[1]	孙兴璐, 陈彻. Egr1在肝癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 435-439.
[2]	李雄, 姜文凯, 郎泽昆, 芮少珍. 肿瘤相关中性粒细胞与胰腺癌关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 458-462.
[3]	李智慧, 李志高. 恩美曲妥珠单抗T-DM1在HER2阳性乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 477-482.
[4]	赵雅茹, 武云. 胃癌常见生物标记物及相应靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 483-488.
[5]	董琳, 刘欣, 鲁海玲. 晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 351-355.
[6]	李原, 张玲. 消化系统肿瘤发生有丝分裂危象的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 356-359.
[7]	梁洁, 王新华, 王健, 夏欢. 非远处转移性甲状腺乳头状癌¹³¹I疗效预测模型的分析[J]. 实用肿瘤学杂志, 2022, 36(3): 220-225.
[8]	唐如冰, 王琪, 游雪梅. 肝癌共病抑郁分子机制的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 239-244.
[9]	于晓兰, 刘艳, 刘家仁. 植物花青素对肿瘤抑制作用的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 245-249.
[10]	郑艳丽, 贺建霞. 弥漫大B细胞淋巴瘤的DNA甲基化改变及治疗进展[J]. 实用肿瘤学杂志, 2022, 36(3): 259-262.
[11]	刘婉莹, 庞达. 乳腺浸润性微乳头状癌转移机制的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 268-272.
[12]	童曼琳, 尚茹茹, 刘晓红. PD-1/PD-L1免疫检查点抑制剂在多形性胶质母细胞瘤中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 278-282.
[13]	陈素, 隋红. 抗HER2治疗在转移性结直肠癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 288-292.
[14]	胡宗涛, 刘演, 高世乐, 甘晨, 张永康. 高剂量少分次放疗联合白蛋白结合型紫杉醇、替吉奥方案化疗在局部晚期胰腺癌患者中的临床疗效以及安全性评价[J]. 实用肿瘤学杂志, 2022, 36(2): 144-149.
[15]	吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.